Fierce Pharma Week 2025: Building audiences with the same data that built the drug
Thank you for visiting HealthVerity at Fierce 2025 HealthVerity had a fantastic week at Fierce...
Topic
HEOR
Disparities in OUD treatment: Buprenorphine vs. naltrexone
Understanding disparities in opioid use disorder (OUD) treatment Pharmaceutical companies committed...
Gilead uses HealthVerity data to find liver-protective treatment
Antiretroviral therapy (ART) has transformed outcomes for people living with HIV, especially those...
How government agencies use HealthVerity for public health and AI-powered research
Government health agencies are increasingly turning to real-world data (RWD) for public health...
HealthVerity real-world data supports CDC study on HIV PrEP surveillance
A new peer-reviewed study from the Centers for Disease Control and Prevention (CDC) highlights the...
HealthVerity at ISPOR 2025: Solving RWD Challenges in Pharma and HEOR
Thank you to everyone who joined us at ISPOR 2025 in Montreal. Whether you stopped by our booth,...
How to optimize real-world data with lab results for clinical trials & HEOR
Key benefits of real-world lab data for life sciences and pharma Real-world lab results enhance...
Advancing COVID-19 Research with the National Cancer Institute
Background While the COVID-19 pandemic is behind us, the virus remains a concern that needs to be...
Extending value long after the clinical trial with real-world data
In our ongoing series, we have been discussing the value of real-world data (RWD) throughout the...
Honoring MOM: How far we've come
Two years ago, HealthVerity launched the Maternal Outcomes Masterset (MOM) to address the...